Global Endoscopic Hemostasis Devices (General Surgery) Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Global Endoscopic Hemostasis Devices (General Surgery) Market Segmentation, By Mechanical Devices (Clips, Ligation Devices, Suturing Devices and Stents) Injection Devices (Injection and Needles), Thermal Devices (Hemostatic Probes, Hemostatic Forceps, Heater Probe, Argon Plasma Coagulation, Radiofrequency Ablation and Cryotherapy), Topical Devices (Hemostatic Spray and Others), End User Industry (Hospitals, Specialty Clinics, Ambulatory Surgical Centers and Others) - Industry Trends and Forecast to 2032

Endoscopic Hemostasis Devices (General Surgery) Market Size

• The global endoscopic hemostasis devices (General Surgery) market size was valued at USD 1.59 billion in 2024 and is expected to reach USD 2.57 billion by 2032, at a CAGR of 6.21% during the forecast period
• The market growth is largely fueled by the rising prevalence of gastrointestinal bleeding, expanding geriatric population, and advancements in minimally invasive surgical procedures, particularly in gastrointestinal endoscopy
• Furthermore, increasing clinical preference for endoscopic interventions over traditional open surgeries due to lower complication rates and faster patient recovery is driving widespread adoption. These converging factors are accelerating the deployment of hemostasis solutions in endoscopic procedures, thereby significantly boosting the industry’s growth

Endoscopic Hemostasis Devices (General Surgery) Market Analysis

• Endoscopic hemostasis devices, enabling precise control of gastrointestinal bleeding during minimally invasive procedures, are becoming essential tools in modern surgical and diagnostic endoscopy due to their clinical effectiveness, reduced procedural invasiveness, and compatibility with advanced endoscopic platforms
• The increasing global incidence of gastrointestinal bleeding, growing geriatric population, and expanding preference for minimally invasive treatments are key drivers accelerating the demand for endoscopic hemostasis solutions in hospitals and ambulatory care centers
• North America dominated the endoscopic hemostasis devices (General Surgery) market with the largest revenue share of 39.2% in 2024, driven by widespread access to endoscopy services, favorable reimbursement structures, and the presence of major medical device companies innovating in hemostatic technologies, particularly in the U.S.
• Asia-Pacific is expected to be the fastest growing region in the endoscopic hemostasis devices (General Surgery) market during the forecast period due to rapidly improving healthcare infrastructure, rising awareness about GI disorders, and growing investments in advanced endoscopic equipment
• Argon Plasma Coagulation segment dominated the endoscopic hemostasis devices (General Surgery) market with a market share of 32.1% in 2024, driven by its non-contact coagulation capability, uniform tissue coverage, and high efficacy in managing diffuse or hard-to-reach gastrointestinal bleeding

Report Scope and Endoscopic Hemostasis Devices (General Surgery) Market Segmentation

Endoscopic Hemostasis Devices (General Surgery) Market Trends

“Technological Advancements and Device Miniaturization Enhancing Procedural Efficiency”

• A significant and accelerating trend in the global endoscopic hemostasis devices market is the advancement and miniaturization of bleeding control tools integrated with improved energy delivery systems and multifunctional capabilities. These innovations are significantly improving procedural precision and reducing complications during gastrointestinal endoscopic interventions

  • For instance, Olympus has developed enhanced rotatable clip systems that allow for precise placement in challenging anatomical locations, while Boston Scientific’s hemostatic powder products offer rapid control of non-localized bleeding, particularly useful in emergency endoscopy settings

• Thermal technologies such as Argon Plasma Coagulation (APC) have evolved with better targeting accuracy and safety, allowing consistent treatment of superficial vascular lesions and radiation-induced bleeding, especially in patients with chronic GI conditions
• The integration of advanced electrosurgical platforms enables real-time control of coagulation intensity and tissue response, offering tailored treatment and minimizing collateral damage. Such innovation is driving greater clinical confidence and widespread adoption across care settings
• This trend towards smarter, compact, and more efficient devices is reshaping clinical expectations in GI bleeding management. Consequently, companies such as ERBE Elektromedizin GmbH are focusing on precision energy systems with customizable modes and safety algorithms for various tissue types
• The demand for endoscopic hemostasis tools that enhance procedural safety and outcomes is growing rapidly across hospitals and ambulatory centers, as healthcare providers prioritize minimally invasive, patient-centric solutions to meet rising GI disorder cases globally

Endoscopic Hemostasis Devices (General Surgery) Market Dynamics

Driver

“Rising GI Disorder Burden and Minimally Invasive Procedure Preference”

• The increasing prevalence of gastrointestinal (GI) bleeding disorders, including ulcers, diverticulosis, and GI malignancies, combined with a growing geriatric population, is a major factor driving the demand for endoscopic hemostasis devices

  • For instance, the rise in emergency GI procedures worldwide has led to higher adoption of advanced hemostasis tools capable of delivering rapid, effective, and minimally invasive intervention. Such devices are becoming essential in treating both acute and chronic GI bleeding cases

• As patients and clinicians increasingly prefer less invasive procedures with faster recovery and fewer complications, endoscopic hemostasis devices offer significant benefits over traditional open surgeries, especially in high-volume hospitals and tertiary care centers
• The ability of these devices to integrate seamlessly with modern endoscopy platforms and support a broad spectrum of bleeding conditions further accelerates their clinical utility and global market penetration

Restraint/Challenge

“High Cost and Limited Access in Resource-Limited Settings”

• Despite their growing importance, the relatively high cost of advanced endoscopic hemostasis devices remains a significant barrier to widespread adoption, especially in low- and middle-income countries with limited healthcare infrastructure

  • For instance, the capital investment required for energy-based systems and specialty devices such as APC or topical sprays can be prohibitive for smaller hospitals, while the need for trained endoscopists and ongoing device maintenance adds to operational costs

• These economic and logistical challenges hinder the availability of minimally invasive hemostasis procedures in underserved regions. In addition, limited awareness and diagnostic capabilities can delay timely intervention
• Overcoming these challenges will require broader policy support, expanded clinician training programs, and the development of cost-effective hemostasis tools to ensure equitable access and sustained global market growth

Endoscopic Hemostasis Devices (General Surgery) Market Scope

The market is segmented on the basis of mechanical devices, injection devices, thermal devices, topical devices, and end user.

• By Mechanical Devices

On the basis of mechanical devices, the endoscopic hemostasis devices (General Surgery) market is segmented into clips, ligation devices, suturing devices, and stents. The clips segment dominated the mechanical devices category with the largest market revenue share of 38.7% in 2024, owing to their effectiveness in managing acute gastrointestinal bleeding and their routine use in procedures such as polypectomy and peptic ulcer therapy. Clips offer rapid deployment, secure closure, and strong mechanical compression, making them a preferred frontline tool for endoscopic hemostasis.

The suturing devices segment is anticipated to witness the fastest growth rate of 20.9% from 2025 to 2032, driven by increasing use in advanced endoscopic procedures such as endoscopic submucosal dissection (ESD) and full-thickness resections. The demand is propelled by a growing preference for minimally invasive closure solutions that reduce the need for surgical intervention.

• By Injection Devices

On the basis of injection devices, the endoscopic hemostasis devices (General Surgery) market is segmented into injection and needles. The injection segment accounted for the largest revenue share of 61.3% in 2024, primarily due to the widespread use of epinephrine injections as the first-line therapy in gastrointestinal bleeding cases. Injections provide immediate vasoconstriction and tissue tamponade, making them indispensable in both diagnostic and therapeutic endoscopy.

The needles segment is projected to grow at the fastest CAGR of 17.5% from 2025 to 2032, driven by advancements in precision delivery systems and the expanding use of injectable agents such as sclerosants and tissue adhesives for targeted hemostatic control.

• By Thermal Devices

On the basis of thermal devices, the endoscopic hemostasis devices (General Surgery) market is segmented into hemostatic probes, hemostatic forceps, heater probe, argon plasma coagulation (APC), radiofrequency ablation (RFA), and cryotherapy. The argon plasma coagulation segment led the market with the largest share of 32.1% in 2024, owing to its ability to provide uniform, non-contact coagulation across large mucosal areas. Its proven clinical efficacy in conditions such as angiodysplasia, radiation proctitis, and bleeding ulcers has made it the dominant thermal modality.

The radiofrequency ablation segment is expected to witness the fastest growth rate of 22.4% from 2025 to 2032, fueled by its precision, depth control, and rising application in chronic bleeding conditions and dysplastic Barrett's esophagus. RFA is increasingly being adopted due to its tissue selectivity and reduced post-procedural complications.

• By Topical Devices

On the basis of topical devices, the endoscopic hemostasis devices (General Surgery) market is segmented into hemostatic spray and others. The hemostatic spray segment dominated with the largest market revenue share of 67.5% in 2024, driven by its non-contact, wide-coverage application ideal for diffuse bleeding, especially in inaccessible anatomical sites. Hemostatic sprays are easy to use and provide immediate coverage, making them a preferred option in emergency situations and for patients with coagulopathies.

The others segment, which includes novel agents such as powders and gels, is anticipated to register the fastest CAGR of 20.7% from 2025 to 2032, driven by innovations in nanoparticle and bioadhesive technologies offering faster clot formation and greater mucosal adherence.

• By End User Industry

On the basis of end user industry, the endoscopic hemostasis devices (General Surgery) market is segmented into hospitals, specialty clinics, ambulatory surgical centers, and others. The hospitals segment led the market with the highest revenue share of 44.6% in 2024, due to the high procedural volumes, presence of advanced surgical infrastructure, and accessibility to multidisciplinary care for complex gastrointestinal cases. Hospitals are the primary setting for both elective and emergency endoscopic hemostasis interventions.

The ambulatory surgical centers (ASCs) segment is expected to record the fastest growth rate of 19.2% from 2025 to 2032, as the demand for cost-effective, outpatient endoscopic solutions rises. ASCs offer quicker turnaround times, minimal hospital stays, and are increasingly equipped with advanced hemostasis tools tailored for routine endoscopy.

Endoscopic Hemostasis Devices (General Surgery) Market Regional Analysis

• North America dominated the endoscopic hemostasis devices (General Surgery) market with the largest revenue share of 39.2% in 2024, driven by widespread access to endoscopy services, favorable reimbursement structures, and the presence of major medical device companies innovating in hemostatic technologies, particularly in the U.S
• The region benefits from advanced healthcare infrastructure, favorable reimbursement policies, and the early adoption of innovative endoscopic technologies in hospitals and ambulatory centers
• A rising geriatric population, increasing awareness of GI bleeding management, and strong presence of leading medical device manufacturers continue to support market expansion, making North America a core hub for endoscopic hemostasis device deployment in both emergency and elective procedures

U.S. Endoscopic Hemostasis Devices (General Surgery) Market Insight

The U.S. endoscopic hemostasis devices (General Surgery) market accounted for the largest revenue share of 84.2% in North America in 2024, driven by the rising prevalence of gastrointestinal bleeding and increasing adoption of minimally invasive procedures. Advanced healthcare infrastructure, strong reimbursement frameworks, and early adoption of cutting-edge technologies such as argon plasma coagulation and hemostatic sprays continue to support the U.S. market. In addition, growing investments in GI endoscopy training and equipment by hospitals and ASCs are significantly boosting demand.

Europe Endoscopic Hemostasis Devices (General Surgery) Market Insight

The Europe endoscopic hemostasis devices (General Surgery) market is projected to register a notable CAGR during the forecast period, driven by rising healthcare expenditures and increased procedural volumes for GI-related disorders. The growing preference for minimally invasive surgeries, coupled with widespread implementation of colorectal cancer screening programs, is fostering the adoption of advanced hemostasis tools. Countries such as Germany, France, and Italy are leading the regional growth, supported by a well-established clinical infrastructure and aging population.

U.K. Endoscopic Hemostasis Devices (General Surgery) Market Insight

The U.K. endoscopic hemostasis devices (General Surgery) market is expected to expand at a healthy CAGR over the forecast period, fueled by a surge in endoscopic procedures for gastrointestinal bleeding and ulcer treatment. Government-supported screening programs, coupled with the adoption of novel technologies such as hemostatic sprays and APC systems, are driving growth. In addition, increasing healthcare digitization and hospital modernization initiatives are further accelerating device utilization in specialty clinics and day-care centers.

Germany Endoscopic Hemostasis Devices (General Surgery) Market Insight

The Germany endoscopic hemostasis devices (General Surgery) market is projected to hold a leading share within Europe’s market, owing to its robust medical device infrastructure, well-developed endoscopy centers, and emphasis on technological innovation. The high procedural rates for GI diagnostics and therapeutic interventions, especially in urban hospitals, are contributing to demand. Furthermore, increasing physician preference for thermal and topical hemostatic techniques is supporting strong adoption trends.

Asia-Pacific Endoscopic Hemostasis Devices (General Surgery) Market Insight

The Asia-Pacific endoscopic hemostasis devices (General Surgery) market is expected to grow at the fastest CAGR of 23.6% from 2025 to 2032, driven by the rising incidence of GI disorders, expanding medical tourism, and rapidly improving healthcare infrastructure across countries such as China, India, and Japan. Government investments in public healthcare systems and increasing awareness regarding early detection of gastrointestinal conditions are supporting market penetration. In addition, local production and affordability of endoscopic equipment are making advanced care accessible to broader populations.

Japan Endoscopic Hemostasis Devices (General Surgery) Market Insight

The Japan endoscopic hemostasis devices (General Surgery) market is gaining traction due to its technologically advanced healthcare system, strong geriatric demographic, and high rate of endoscopic procedures. The adoption of minimally invasive endoscopic hemostasis tools is driven by clinical preference for precision and safety. Japan’s leading medical universities and hospitals are actively integrating innovative coagulation and spray-based technologies for better patient outcomes, contributing to steady market expansion.

India Endoscopic Hemostasis Devices (General Surgery) Market Insight

The India endoscopic hemostasis devices (General Surgery) market captured the largest revenue share in Asia-Pacific in 2024, supported by its rapidly growing healthcare infrastructure, increasing prevalence of gastrointestinal disorders, and expanding public-private partnerships. The affordability of advanced endoscopic tools, rising number of skilled gastroenterologists, and the push toward modernizing rural and urban healthcare facilities are accelerating adoption. Government initiatives promoting early cancer screening and endoscopy awareness are also positively impacting the market.

Endoscopic Hemostasis Devices (General Surgery) Market Share

The endoscopic hemostasis devices (General Surgery) industry is primarily led by well-established companies, including:

• Boston Scientific Corporation (U.S.)
• CONMED Corporation (U.S.)
• Cook (U.S.)
• Diversatek, Inc. (U.S.)
• Olympus America (Japan)
• STERIS (U.S.)
• MICRO-TECH (Nanjing) Co., Ltd. (China)
• Integra LifeSciences Corporation (U.S.)
• Sklar Surgical Instruments (U.S.)
• Merit Medical Systems (U.S.)
• Abbott (U.S.)
• Siemens (Germany)
• HORIBA, Ltd. (Japan)
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China)
• Nova Biomedical (U.S.)
• Sysmex (Japan)
• BD (U.S.)

What are the Recent Developments in Global Endoscopic Hemostasis Devices (General Surgery) Market?

• In April 2023, Olympus Corporation launched the QuickClip Pro hemostatic clip in multiple global markets, designed to improve precision and control during endoscopic procedures. This new clip enables rapid deployment and enhanced rotation control, supporting improved outcomes in gastrointestinal bleeding management. The innovation reflects Olympus’ commitment to advancing therapeutic endoscopy and expanding its portfolio of high-performance hemostasis solutions
• In March 2023, Boston Scientific Corporation introduced its next-generation Resolution 360 ULTRA Clip in the U.S. and Europe, engineered to provide superior rotation and grip force for complex GI bleeding scenarios. This upgrade enhances procedural efficiency and clinical accuracy, underlining Boston Scientific’s continued focus on device innovation and meeting the evolving needs of endoscopists worldwide
• In March 2023, Cook Medical announced expanded availability of its Instinct Plus Endoscopic Hemoclip, which offers enhanced opening width and repositioning capabilities to support a broader range of GI bleeds. The device’s improved visibility and anchoring features help clinicians manage difficult bleeds with greater ease and precision. This development illustrates Cook Medical’s dedication to simplifying complex endoscopic interventions
• In February 2023, CONMED Corporation revealed advancements to its Beamer Platform, incorporating optimized argon plasma coagulation (APC) settings and safety features tailored for therapeutic endoscopy. The platform upgrade facilitates improved energy delivery and tissue interaction, enabling consistent coagulation in a range of GI bleeding cases. This reinforces CONMED’s role in delivering cutting-edge energy-based hemostasis technologies
• In January 2023, ERBE Elektromedizin GmbH showcased its latest VIO 3 electrosurgical unit and APC 3 system at the Arab Health 2023 conference, emphasizing greater user customization, intuitive controls, and integration with high-frequency endoscopy tools. These innovations are aimed at advancing GI therapeutic procedures through greater precision and safety. The launch highlights ERBE’s continued investment in thermal hemostasis technologies to support global endoscopic practices

SKU-67600